Aptevo Therapeutics (APVO) Cost of Revenue (2016 - 2019)
Historic Cost of Revenue for Aptevo Therapeutics (APVO) over the last 5 years, with Q4 2019 value amounting to $6.1 million.
- Aptevo Therapeutics' Cost of Revenue changed N/A to $6.1 million in Q4 2019 from the same period last year, while for Dec 2019 it was $19.9 million, marking a year-over-year change of. This contributed to the annual value of $19.9 million for FY2019, which is 7769.75% up from last year.
- As of Q4 2019, Aptevo Therapeutics' Cost of Revenue stood at $6.1 million.
- In the past 5 years, Aptevo Therapeutics' Cost of Revenue ranged from a high of $6.5 million in Q2 2016 and a low of $488000.0 during Q1 2017
- In the last 5 years, Aptevo Therapeutics' Cost of Revenue had a median value of $3.9 million in 2019 and averaged $3.8 million.
- Per our database at Business Quant, Aptevo Therapeutics' Cost of Revenue plummeted by 8616.78% in 2017 and then soared by 26495.9% in 2018.
- Quarter analysis of 5 years shows Aptevo Therapeutics' Cost of Revenue stood at $5.2 million in 2015, then dropped by 3.0% to $5.1 million in 2016, then plummeted by 62.68% to $1.9 million in 2017, then increased by 28.53% to $2.4 million in 2018, then skyrocketed by 151.78% to $6.1 million in 2019.
- Its Cost of Revenue was $6.1 million in Q4 2019, compared to $4.0 million in Q3 2019 and $6.0 million in Q2 2019.